Colorectal Cancer – Unmet Need – Detailed, Expanded Analysis (US/EU) Previously Treated RAS and BRAF Mutation-Positive Metastatic Colorectal Cancer

This Unmet Need report focuses on the treatment of previously treated RAS and BRAF  mutation-positive metastatic colorectal cancer. Currently, the NCCN guidelines and treatment practices for metastatic colorectal cancer include the determination of tumor gene status for RAS (KRAS / NRAS) and BRAF  mutation-positive patients. In second- and later-line settings, RAS and BRAF mutation-positive patients are treated with anti-VEGF therapies, such as Avastin (Genentech/Roche), Cyramza (Eli Lilly), Stivarga (Bayer), and Zaltrap (Sanofi / Regeneron), with or without chemotherapy. The novel treatment regimen, consisting of BRAF + MEK inhibitors, Braftovi + Mektovi (Pfizer / Array BioPharma), in combination with the anti-EGFR therapies Erbitux (Eli Lilly / Merck KGaA) or Vectibix (Amgen), is recommended for the subsequent treatment of BRAF  mutation-positive patients. Nevertheless, less-toxic, more-efficacious therapies are needed for the subsequent treatment of these two colorectal cancer subpopulations.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for previously treated RAS / BRAF  mutation-positive metastatic colorectal cancer?
  • What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for previously treated RASBRAF  mutation-positive metastatic colorectal cancer?
  • What are the prevailing areas of unmet need and opportunity in previously treated RAS / BRAF  mutation-positive metastatic colorectal cancer?
  • What trade-offs across different clinical attributes and prices are acceptable to U.S. and European medical oncologists for a hypothetical new RAS / BRAF  mutation-positive metastatic colorectal cancer drug?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 32 European medical oncologists fielded in April 2020

Key companies: Pfizer / Array BioPharma, Eli Lilly / Merck KGaA, Amgen, Roche / Genentech, Bayer, Taiho  Pharmaceutical

Key drugs: Braftovi, Erbitux, Vectibix, Avastin, Cyramza, Stivarga, Lonsurf

Table of contents


launch Related Market Assessment Reports